Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis

Mengqing Xie; Chunxia Su

doi:10.3389/fonc.2022.1006284

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis

Front Oncol. 2023 Jan 24:12:1006284. doi: 10.3389/fonc.2022.1006284. eCollection 2022.

Authors

Mengqing Xie¹, Chunxia Su¹

Affiliation

¹ Department of Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, School of Medicine, Tongji University, Shanghai, China.

Abstract

One of the most frequent distant metastases of lung cancer occurs in the brain. The average natural survival duration for patients with lung cancer who have brain metastases is about 1 to 2 months. Knowledge about brain metastases is currently restricted since they are more difficult to acquire than other metastases. This review begins with an analysis of the immune microenvironment of brain metastases; focuses primarily on the functions of microglia, astrocytes, neurons, and tumor-infiltrating lymphocytes in the microenvironment of brain metastases; and offers an atlas of the immune microenvironment of brain metastases involving significant cells. In an effort to give researchers new research ideas, the study also briefly covers how immunotherapy for non-small cell lung cancer with brain metastases is currently faring.

Keywords: NSCLC; brain metastasis; immunotherapy; organ-specific; time.

Publication types

Review

Grants and funding

This work was supported by the Shanghai Hospital Development Center (grant number: SHDC12020110), the Clinical Research Foundation of ShangHai Pulmonary Hospital (grant number: FKLY20013), and the Excellent Academic Leader of Shanghai “Science and Technology Innovation Action Plan” (grant number: 22XD1402500).